Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545793 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TSHRPOLBGAAGFER | |
| SCHEMBL2045622 | 0.93 | ALDH1A1 (0.42) | ALDH1A1TSHRPOLBGAAGFER | |
| SCHEMBL5881508 | 0.87 | ALDH1A1 (0.40) | ALDH1A1TSHRPOLBGAAGFER | |
| SCHEMBL27600073 | 0.77 | ALDH1A1 (0.39) | ALDH1A1TSHRPOLBGAAGFER | |
| SCHEMBL5548791 | 0.77 | RARG (0.30) | POLBGAAGFER | |
| SCHEMBL5413341 | 0.76 | GLRA1 (0.44) | ALDH1A1MAPTADRA1AMAPK1 | |
| SCHEMBL7592828 | 0.72 | ALDH1A1 (0.41) | ALDH1A1GAACA1CA2CA7 | |
| SCHEMBL8119851 | 0.72 | NFE2L2 (0.43) | ALDH1A1TSHRPOLBGAAGFER | |
| SCHEMBL13395132 | 0.71 | CYP2D6 (0.42) | ALDH1A1TSHRPOLBGAAGFER | |
| SCHEMBL739698 | 0.70 | HDAC4 (0.48) | ALDH1A1TSHRPOLBGAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689383-B1 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2428516-A1 | Novel phosphorus-containing thyromimetics | Metabasis Therapeutics, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7829552-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-05-07 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1689383-A4 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1890768-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2000072811-A1 | METHOD OF TREATING HAIR LOSS | THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) | 2000-12-07 | — | — | WO | disclosed |
| EP-1000008-A1 | NOVEL THYROID RECEPTOR LIGANDS AND METHOD | KARO BIO AB (SE) | 2000-05-17 | — | — | EP | disclosed |
| WO-2000007972-A1 | GLUCOCORTICOID AND THYROID HORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KARO BIO AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999063976-A2 | LIVER-SELECTIVE GLUCOCORTICOID ANTAGONIST FOR TREATING DIABETES | KARO BIO AB (SE) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999000353-A1 | NOVEL THYROID RECEPTOR LIGANDS AND METHOD | KARO BIO AB (SE) | 1999-01-07 | — | — | WO | disclosed |
| EP-0580550-B1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA GEIGY AG (CH) | 1997-10-22 | — | — | EP | disclosed |
| US-5654468-A | ANTILIPID, ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5569674-A | ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-10-29 | — | — | US | disclosed |
| US-5401772-A | Anticholesterol agents with aromatic amines | CIBA-GEIGY CORPORATION (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0580550-A1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA-GEIGY AG (CH) | 1994-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | PYGL, THRA, THOP1 | ALDH1A1 4227/4885TSHR 12/4885POLB 3808/4885 |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | THRA, PYGL, THRB | ALDH1A1 4038/4885TSHR 6/4885POLB 3605/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | ALDH1A1 4147/4885TSHR 20/4885POLB 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.